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Correction
==========

The authors noticed after the publication of their article \[[@B1]\] an error in their methods. Under \"Randomization and treatment assignments\", the Asahi APS 650 membrane was used together with the Octo Nova device (Octo Nova, Diamed, Köln, Germany) and not the Prisma device as indicated in the manuscript. This section should therefore read as follows;

\"Patients randomly assigned to the CVVH-group (Prisma, Gambro Hospal, Lyon, France and Octo Nova, Diamed, Köln, Germany) were treated with 35 ml/kg per hour replacement fluid in predilution. Treatment was scheduled for 24-h and blood flow was maintained between 100 and 120 ml/min. For all CVVH treatments, high-flux filters (AN69-M100, Gambro Hospal, Lyon, France and Asahi Kasei APS-650, Asahi Kasei Medical Co, Ltd., Japan) were used.\"

In addition, the funding of this study was erroneously deleted in-house and should read as follows;

\"Grant of the European Nephrology and Dialysis Institute, Bad Homburg, Germany\".
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